



# **NMRC ROADSHOW SINGAPORE CLINICAL RESEARCH INSTITUTE (SCRI)**


JUNE 2022

# ABOUT SCRI

## Mission

1. **Function as the National Coordinating Body for Clinical Trials to reduce roadblocks and improve the conduct of clinical trials in Singapore.**
2. **Work with Partners to support the conduct of Investigator-initiated trials (IITs) and Industry-sponsored trials (ISTs) in Singapore.**

Clinical Trials Organisation with 26 years of experience supporting clinical trials in Singapore



# SCRI AT A GLANCE (2018 – 2020)

## 93 Active Studies

- 77 distinct PIs out of 93 active studies
- 42 interventional studies and 27 observational / registry studies



**139** Pre-Grant project support provided from 2018 to 2020



**8** Clinical Research Networks Supported  
(9<sup>th</sup> supported network recently launched in 2021)



**116** Journal Publications from 2018 to 2020  
(51 publications with Impact Factor of greater than 3)



**137** Clinical Research Coordinators (CRCs) trained under SCRI Academy from 2018 to 2020  
(76 more CRCs trained in 2021)

# CLINICAL TRIALS SUPPORT OVERVIEW

**SCRI Project Management & Business Operations** assist Investigator with trial budgeting.


 **Budgeting & Grant Application**

**SCRI Project Management & Research Monitoring** help to put together documents for submissions.

 **Regulatory & Ethics Submissions**

**SCRI Project Management** monitor progress of trials.  
**SCRI Research Monitoring** to conduct site monitoring visits.

 **Patient Recruitment & Trial Operations**



 **Protocol Design & Finalisation**

**SCRI Epidemiology & Biostatistics** work with Investigator to design protocol.



 **Trial Startup**


**SCRI Project Management & Research Monitoring** to work with site management teams to ensure site is ready to conduct trial before conducting Site Initiation Visit.  
**SCRI Data Management & Research Informatics** prepare trial database.



 **Trial Closeout & Report**

**SCRI Biostatistics** to analyse trial data for closeout report.  
**SCRI Project Management** assist Investigator with report submission.

## ARO Capabilities:



# FLEXIBLE MODELS OF PARTNERSHIP/ENGAGEMENT

Possible Engagement Models:



## Industry Fee-for-Service

- Industry-Sponsored Trials
- Competitive Service Rates
- Service Agreement



## Industry Collaborations

- Industry-Sponsored Trials
- Discounted from Full-price Rates
- In-kind contributions from SCRI
- Collaborative Agreement



## Academic Fee-for-Service

- Investigator-Initiated Trials
- Discounted Academic Rates
- Service Agreement



## Academic Collaborations

- Investigator-Initiated Trials
- In-kind contributions from SCRI
- Co-applicant for grants
- Collaborative Agreement

- For all engagements, we prefer partners to approach us early, in particular **BEFORE** grant application for IITs so that we can contribute to your proposal and help you with scoping out of the requirements and budget.

# FEASIBILITY ASSESSMENTS

- A major point of consideration for review panels when assessing funding proposals for clinical studies is whether there are sufficient patients to complete the studies proposed.
- The Oncoshot Feasibility Platform provides investigators and biotech/pharmaceutical companies with accurate up-to-date information on oncology patient numbers based on the inclusion/exclusion criteria of the study proposed.
- These information are provided within the framework of Security and Privacy that is within the access control of the various sites contributing the data.



# FEASIBILITY ASSESSMENTS

On 6<sup>th</sup> April 2022, SCRI signed an MOU with local company Oncoshot to provide Oncoshot's Feasibility Assessment Platform to public sector oncology investigators at **no cost**.



# FEASIBILITY ASSESSMENTS

## STRENGTHEN YOUR GRANT APPLICATION WITH REAL-TIME DATA USING THE ONCOSHOT FEASIBILITY PLATFORM

Dashboard / Clinical Trials / OS0062 / Feasibility Questionnaire...

### Feasibility Questionnaire

**Instructions & basic information**

1. Study team is to complete the form after reviewing the synopsis, protocols, and other sponsor materials.
2. Your responses to this questionnaire will be used to estimate your institution's capability to participate in the trial.

**Study Details**

**Trial name:**  
Advanced haemotologic malignancies with IDH1 and IDH2 mutations

**Trial number:**  
OS0062

**Site details**

**Site Name:**  
National Cancer Centre Singapore

**Address:**  
11 Hospital Crescent, Singapore 169610

**1. Study team**

Principal investigator has more than two years of experience conducting ICH GCP trials?

Yes  No

Yes

Practical experience with the study drug?

Yes  No

Yes

**Steps:**

1. Study team
2. Patient en
3. Ethics
4. Site facilit
5. Site feedb
6. Attached
7. Study par

No

Comments

**6. Attached files**

⬆️ Drag and drop or click to upload files

**7. Study participation**

Do you agree to participate in the trial and accept all the formal requirements including GCP, national laws, audits, archiving, etc.?

Yes  No

**I consent to:**

1. The processing (including the collection, use, disclosure and transfer) of the information shared in this form, pursuant to any or future study
2. The inclusion of my personal data (i.e., contact details and professional information) in the sponsor database
3. Being contacted by mail, facsimile, electronic mail or other electronic means, over possible participation in current and future studies

I agree to the above \*

**Submit** **Save** **Cancel**



# CONTACT DETAILS

Email: [contact@scri.cris.sg](mailto:contact@scri.cris.sg)

Address: 23 Rochester Park, #06-01. Singapore 139234